Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Antonio Tauler

Psychiatry Coral Gables, FL Medical Doctor

NPI 1851342844 CMS profile 1070673

3850 W Flagler St, Coral Gables, FL 33134

Open in the dashboard

General payments

$10,916

638 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Antonio Tauler of Coral Gables, FL is reported in the CMS Open Payments database as having received $10,916 across 638 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,738 144
2024 General $2,199 114
2023 General $2,111 106
2022 General $1,451 77
2021 General $318 16
2020 General $401 27
2019 General $1,698 154

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Antonio Tauler
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Antonio Tauler were reported at $2,738. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Antonio Tauler Psychiatry median Middle half National median
2019 $1,698 $184 $59–$605 $163
2020 $401 $119 $36–$372 $114
2021 $318 $143 $43–$576 $132
2022 $1,451 $153 $50–$590 $149
2023 $2,111 $170 $56–$651 $160
2024 $2,199 $179 $57–$673 $164
2025 $2,738 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,876 111 payments
  2. Otsuka America Pharmaceutical, Inc. $1,368 70 payments
  3. Teva Pharmaceuticals USA, Inc. $1,224 102 payments
  4. Janssen Pharmaceuticals, Inc $818 44 payments
  5. Alkermes, Inc. $675 36 payments
  6. Lundbeck LLC $625 33 payments
  7. ITI, Inc. $581 30 payments
  8. Allergan Inc. $544 47 payments
  9. Sunovion Pharmaceuticals Inc. $493 46 payments
  10. E.R. Squibb & Sons, L.L.C. $464 18 payments
  11. Other $2,249 101 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,805 637 payments
  2. Education $111 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $1,520 87 payments
  2. VRAYLAR Neuroscience $872 68 payments
  3. REXULTI Psychiatry $746 40 payments
  4. INVEGA SUSTENNA $685 38 payments
  5. REXULTI Psychiatry $571 30 payments
  6. LYBALVI $544 30 payments
  7. AUSTEDO $505 60 payments
  8. LATUDA $493 46 payments
  9. Austedo XR $452 34 payments
  10. CAPLYTA $429 22 payments
  11. Other $6,865 339 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

12,765

Median for Psychiatry: 574

Drug cost

$929,437

Median for Psychiatry: $27,624

Branded share of claims

9.7%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 161 $227,272
Rexulti Brexpiprazole Brand 143 $213,442
Austedo Xr Deutetrabenazine Brand 17 $206,718
Aripiprazole Generic 505 $95,096
Quetiapine Fumarate Generic 682 $15,713
Clozapine Generic 91 $13,220
Risperdal Consta Risperidone Microspheres Brand 11 $12,978
Namzaric Memantine Hcl/Donepezil Hcl Brand 21 $12,611
Belsomra Suvorexant Brand 27 $12,472
Olanzapine Generic 275 $11,712

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $239
  • Lundbeck LLC $166
$405 143 —
VRAYLAR
  • AbbVie, Inc. $362
$362 161 —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $200
$200 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $141
$141 17 —
Auvelity
  • Axsome Therapeutics, Inc. $131
$131 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

638 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record